Eosinophil and mast cell Siglecs: From biology to drug target.
J Leukoc Biol
; 108(1): 73-81, 2020 07.
Article
en En
| MEDLINE
| ID: mdl-31965606
Mast cells and eosinophils are innate immune cells involved in both acute and chronic inflammatory responses. Siglecs are a family of cell surface receptors that share sialic acid binding activity. Over the past 20 years, our knowledge of the expression and function of Siglecs on cells of the immune system and others has greatly expanded, as has our understanding of their signaling, ligands, and possible roles in disease pathophysiology. Because of this, Siglecs have garnered interest as potential drug targets using strategies ranging from biologics to ligand-directed nanoparticles. This mini-review will highlight the state of our knowledge regarding human eosinophil and mast cell Siglecs, their biology, what they recognize, tools developed for in vitro and preclinical experimentation, and the status of ongoing efforts to develop drugs that engage eosinophil and mast cell Siglecs for potential therapeutic benefit.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Sistemas de Liberación de Medicamentos
/
Eosinófilos
/
Lectinas Similares a la Inmunoglobulina de Unión a Ácido Siálico
/
Mastocitos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Leukoc Biol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos